Adverse events55

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 55

Type	Event	Organ system	Group	Affected	At risk	Events
other	akathisia	Musculoskeletal and connective tissue disorders	Period 1: Initital 2-week Treatment - Amisulpride Treated Patients	10	163	10
other	akathisia	Musculoskeletal and connective tissue disorders	Period 1: Initital 2-week Treatment - Olanzapine Treated Patients	2	164	2
other	akathisia	Musculoskeletal and connective tissue disorders	Period 2: Extended 6-week Treatment - Early Responders	7	140	7
other	akathisia	Musculoskeletal and connective tissue disorders	Period 2: Extended 6-week Treatment - Early Non-responders Switched	3	70	3
other	akathisia	Musculoskeletal and connective tissue disorders	Period 2: Extended 6-week Treatment - Early Non-responders Not Switched	1	72	1
other	tremor	Musculoskeletal and connective tissue disorders	Period 1: Initital 2-week Treatment - Amisulpride Treated Patients	10	163	10
other	tremor	Musculoskeletal and connective tissue disorders	Period 1: Initital 2-week Treatment - Olanzapine Treated Patients	7	164	7
other	tremor	Musculoskeletal and connective tissue disorders	Period 2: Extended 6-week Treatment - Early Responders	8	140	8
other	tremor	Musculoskeletal and connective tissue disorders	Period 2: Extended 6-week Treatment - Early Non-responders Switched	4	70	4
other	tremor	Musculoskeletal and connective tissue disorders	Period 2: Extended 6-week Treatment - Early Non-responders Not Switched	2	72	2
other	weight increase	Metabolism and nutrition disorders	Period 1: Initital 2-week Treatment - Amisulpride Treated Patients	7	163	7
other	weight increase	Metabolism and nutrition disorders	Period 1: Initital 2-week Treatment - Olanzapine Treated Patients	12	164	12
other	weight increase	Metabolism and nutrition disorders	Period 2: Extended 6-week Treatment - Early Responders	4	140	4
other	weight increase	Metabolism and nutrition disorders	Period 2: Extended 6-week Treatment - Early Non-responders Switched	1	70	1
other	weight increase	Metabolism and nutrition disorders	Period 2: Extended 6-week Treatment - Early Non-responders Not Switched	1	72	1
other	headache	Nervous system disorders	Period 1: Initital 2-week Treatment - Amisulpride Treated Patients	3	163	3
other	headache	Nervous system disorders	Period 1: Initital 2-week Treatment - Olanzapine Treated Patients	4	164	4
other	headache	Nervous system disorders	Period 2: Extended 6-week Treatment - Early Responders	6	140	6
other	headache	Nervous system disorders	Period 2: Extended 6-week Treatment - Early Non-responders Switched	4	70	4
other	headache	Nervous system disorders	Period 2: Extended 6-week Treatment - Early Non-responders Not Switched	1	72	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01029769/events

API reference For AI assistants

Adverse events55

Sources 3

Read this list from software.